The University of Texas MD Anderson Cancer Center received a $267,527 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for a research project titled "Targeting SMARCA2 to Overcome Resistance of SMARCA4-Mutant Lung Cancer to KRAS G12C Inhibitors". The primary goal of this 2-year project is to investigate the mechanisms of resistance to KRAS G12C inhibitors in lung cancer with SMARCA4 mutations, and to evaluate the potential of using SMARCA2-degrading molecules as a strategy to overcome this resistance. The research will utilize in-depth molecular characterization, development of resistant cell lines, and in vivo efficacy studies to elucidate the interaction between the KRAS and SMARCA2/4 pathways. Findings from this work are expected to have broader implications for improving outcomes with KRAS-targeted therapies across multiple cancer types.
Generated 3/4/25, 5:52 AM